CD19 and lymphoma: Another study on PD-1 KD CD19 targeted CAR T cells against relapsed/refractory B cell malignancies reported a 6/16 (37.5%) CR (3/4 in B-ALL, 2/8 in DLBCL, 1/2 in follicular lymphoma), and the three lymphoma responders did not relapse in the follow-up period [250].